✨ Free AI Report
Mainz Biomed N.V.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Mainz Biomed N.V.
Company Research

Mainz Biomed N.V.: Business Overview, Financials & Competitive Analysis

Mainz Biomed N.V. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage cancer diagnostic biotech with strong clinical data but facing typical micro-cap biotech cash constraints and regulatory pathway execution risks. The company faces cash constraints typical of micro-cap biotech, with a $3 million August 2025 offering representing minimal capital for a diagnostics company with high development costs. However, recent.

What is Mainz Biomed N.V.'s industry? Mainz Biomed N.V. (mainzbiomed.com) operates in Molecular Genetics Diagnostics / In-Vitro Diagnostics (IVD) - Cancer Screening. AskCyborg classifies Mainz Biomed N.V. under Molecular Genetics Diagnostics / In-Vitro Diagnostics (IVD) - Cancer Screening in its company registry.

Mainz Biomed develops and sells in-vitro diagnostic tests for early detection of cancer, with its flagship product ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. Founded in 2008 and based in M...

5/ 10Mixed

Cyborg Score thesis

Early-stage cancer diagnostic biotech with strong clinical data but facing typical micro-cap biotech cash constraints and...

Read the full analyst-debate transcript →
Industry Molecular Genetics Diagnostics / In-Vitro Diagnostics (IVD) - Cancer Screening
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Mainz Biomed N.V. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Mainz Biomed N.V.

AskCyborg analysts argue the bull and bear cases for Mainz Biomed N.V. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Mainz Biomed N.V. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Mainz Biomed N.V. Overview

Pro stress-test →

Mainz Biomed develops and sells in-vitro diagnostic tests for early detection of cancer, with its flagship product ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. Founded in 2008 and based in Mainz, Germany, the company is advancing next-generation cancer screening solutions with expanded pipeline candidates.

Strategic Profile

Pro stress-test →

The company is focusing on a next-generation screening test with mRNA biomarkers that detects both colorectal cancer and advanced adenomas, seeking reimbursement and guideline inclusion. Mainz Biomed has a collaboration agreement with Thermo Fisher Scientific for colorectal cancer screening product development and commercialization. In 2025, the company entered into a licensing agreement with Liquid Biosciences for mRNA biomarkers enabling a blood-based pancreatic cancer screening test for potential FDA applications.

Competitive Landscape

Pro stress-test →

Mainz Biomed competes in the non-invasive cancer screening market against companies offering FIT tests, colonoscopy alternatives, and emerging blood-based screening platforms. Competitors include Check-Cap, ENDRA Life Sciences, and established IVD players. Differentiation rests on proprietary mRNA biomarker technology and multi-cancer capability development.

Industry Context

Mainz Biomed N.V. operates in Molecular Genetics Diagnostics / In-Vitro Diagnostics (IVD) - Cancer Screening.

Key facts

Founded: 2008 · Headquarters: Mainz, Germany · Market cap: $95.7M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Mainz Biomed N.V..

  • Next-generation CRC test with mRNA biomarkers demonstrated strong performance; eAArly DETECT 2 study launched in 2025 to validate on average-risk populations for FDA pivotal trial preparation
  • ColoAlert received MHRA registration for UK market (2025) and added to DoctorBox digital health platform in Germany; expanding European commercial footprint
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 20262025 year-end highlights review; full financial results expected March 2026
  • November 2025Showcased cancer detection solutions at MEDICA 2025; ColoAlert and next-gen diagnostic solutions featured
  • +2 moreTrack every material event for Mainz Biomed N.V. as it happens. Explore monitoring →
Get alerted when Mainz Biomed N.V. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

FIT TestingFecal immunochemical tests for occult blood screening; globally most-used non-invasive CRC test→ColonoscopyGold-standard invasive colorectal cancer screening requiring procedure infrastructure→Check-CapAlternative CRC screening solutions competing in non-invasive diagnostics space→

Compare Mainz Biomed N.V. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Mainz Biomed N.V. operates in Molecular Genetics Diagnostics / In-Vitro Diagnostics (IVD) - Cancer Screening. See how the rest of the sector scores on the Cyborg framework.

Browse Molecular Genetics Diagnostics / In-Vitro Diagnostics (IVD) - Cancer Screening research →
NEW · MCP server

Ask your AI assistant about Mainz Biomed N.V.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Mainz Biomed N.V. and its top competitor on Cyborg Score”
“What did Mainz Biomed N.V. do this quarter?”
“Is Mainz Biomed N.V. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Mainz Biomed N.V. do?+
Mainz Biomed develops and sells in-vitro diagnostic tests for early detection of cancer, with its flagship product ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. Founded in 2008 and based in M...
What is Mainz Biomed N.V.'s Cyborg Score?+
Mainz Biomed N.V. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Mainz Biomed N.V.'s main competitors?+
Named competitors include FIT Testing, Colonoscopy, Check-Cap. The full competitive landscape is in the AskCyborg report.
How can I get the full Mainz Biomed N.V. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Mainz Biomed N.V. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Mainz Biomed N.V. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.